奥美拉唑对环丙沙星口服缓释制剂生物利用度的影响。
Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin.
作者信息
Washington Carla, Hou Eddie, Hughes Nicki, Berner Bret
机构信息
Clinical Pharmacokinetics, Depomed Inc., 1360 O'Brien Drive, Menlo Park, CA 94025-1436, USA.
出版信息
Am J Health Syst Pharm. 2006 Apr 1;63(7):653-6. doi: 10.2146/ajhp050355.
PURPOSE
The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release (ER) ciprofloxacin was studied.
METHODS
A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography.
RESULTS
Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria.
CONCLUSION
Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.
目的
研究奥美拉唑对Depomed公司的缓释环丙沙星制剂口服生物利用度和尿液暴露量的影响。
方法
在健康受试者中进行了一项双向交叉研究。受试者接受单剂量1000 mg缓释环丙沙星，或在接受三天40 mg奥美拉唑治疗后接受单剂量1000 mg缓释环丙沙星。在36小时内采集血液和尿液样本，使用高效液相色谱法测定环丙沙星浓度。
结果
27名受试者（16名男性，11名女性）接受了两种治疗。两种治疗之间的平均最大浓度、血浆浓度-时间曲线下平均面积以及尿液中环丙沙星的平均排泄量相似，符合严格的生物等效性标准。
结论
奥美拉唑不影响口服缓释环丙沙星制剂的血浆或尿液药代动力学。
Zotero 插件